Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Ibritumomab tiuxetan Stories

2008-09-17 12:00:35

InNexus Biotechnology, a drug development company, has announced the results of an extensive mouse tumor study demonstrating superiority of the company's DXL625 compared to Rituxan in the xenograft model. The company has also launched a large scale study of DXL625 with primates, designed to evaluate toxicity and pharmokinetics, enabling the company to move the product to the FDA toward human testing. Thomas Kindt, InNexus's chief scientific officer, said: "A study performed by an...

2008-09-02 09:00:43

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the appointment of Patrick O'Connor, PhD, Vice President, Research, Michael J. LaBarre, PhD, Vice President, Product Development, and James E. Cartoni, Vice President, Legal. "Halozyme is committed to attracting, developing, and retaining world- class talent. We are delighted that seasoned...

2008-08-21 09:01:14

SOUTH SAN FRANCISCO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. announced today that Christine A. White, M.D. has been appointed to the company's board of directors. "Christine White brings to our board a wealth of experience in oncology, as a practicing oncologist as well as several years in clinical development and medical affairs in oncology drug development," said William D. Young, Monogram's Chairman and Chief Executive Officer. "With the recent launch of...

2008-08-05 03:00:11

SEATTLE, Aug. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company") (Nasdaq: CTIC; MTA) t announced that Craig W. Philips has assumed his role as CTI's new President, and will concentrate on managing the company's drug development and commercial operations. Most recently, Philips was Vice President and General Manager of Bayer Healthcare Oncology. He will report to CTI's James A. Bianco, M.D., who has served as President and Chief Executive Officer since its founding and will...

2008-07-28 18:00:00

THE TOBACCO plant - responsible for millions of cancer cases - may actually offer the means to treat one form of the disease, a study says. US scientists used the plant to "grow" key components of a cancer vaccine. The National Academy of Sciences study suggests they could be used to tackle a form of lymphoma. UK specialists said while the work is potentially exciting, more research would be needed to test how well the vaccine actually worked. The ironic new role for tobacco is...

2008-07-22 03:00:18

SEATTLE, July 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company has scheduled a meeting with the U.S. Food and Drug Administration (FDA) in September to discuss the possibility of filing a supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. The basis for the...

2008-07-18 09:01:12

Biovest, a subsidiary of Accentia, has announced positive data from a pivotal trial of BiovaxID in lymphoma, and the vaccine now stands a good chance of becoming the first therapeutic cancer vaccine to gain approval in the seven major markets. However, despite this breakthrough, a number of economical and logistical issues could prevent the vaccine from achieving significant market penetration. Biovest's BiovaxID prolonged disease-free survival in patients with follicular lymphoma, meeting...

2008-07-15 21:00:30

SEATTLE, July 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Congress today passed the Medicare Improvements for Patients and Providers Act of 2008, which includes an 18-month extension of the 2007 reimbursement rate for radioimmunotherapies such as Zevalin(R) (Ibritumomab Tiuxetan), overriding President Bush's veto. The bill was originally passed by the U.S. House of Representatives on June 24, 2008 and by the U.S. Senate on July 9, 2008....

2008-06-25 03:01:25

By Wahl, Richard L Many of us remember the 1989 film Field of Dreams, starring Kevin Costner. In brief, the main character becomes convinced that a baseball field must be built on his failing farmland. Another character assures him that if he builds it, "they" will come. And come they did, not only within the storyline of the movie but, as a result of the movie's popularity, to the real field in Dyersville, IA. After some contention between the 2 adjacent landowners, the field created for...

2008-06-20 03:00:29

SEATTLE, June 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) held a Special Meeting in lieu of the Annual Meeting of Shareholders on Thursday, June 19, 2008 at its headquarters in Seattle. At the meeting, shareholders approved all matters with more than 95 percent of votes cast at the meeting voting in favor of each of the items proposed in the Company's Proxy Statement, including the reelection of directors Frederick Telling, M.D. Vartan Gregorian, Ph.D., and...